Co­herus Bio­Sciences lays off 20% of staff, while an­timi­cro­bial biotech makes deep­er cuts

More lay­offs have hit the biotech in­dus­try this week, with Co­herus Bio­Sciences say­ing it let go about 60 em­ploy­ees and an an­timi­cro­bial drug de­vel­op­er part­ing ways with 30% of its staff.

The lay­offs at Co­herus, an im­muno-on­col­o­gy biotech and mak­er of biosim­i­lars, equate to rough­ly 20% of the 359 full-time and part-time em­ploy­ees it had at the end of 2022, all based in the US. The Red­wood City, CA biotech dis­closed the news in its quar­ter­ly up­date. In an SEC fil­ing, Co­herus said most of the lay­offs would go in­to ef­fect on Fri­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.